Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Ensayo in vitro de la respuesta inmune humana

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TONL20170201001
Publicado:
25/04/2017
Caducidad:
25/04/2018
Resumen:
Una joint-venture holandesa-británica está desarrollando un sistema de ensayos biológicos y analíticos que combina nuevas líneas celulares, andamios 3D y células primarias para suministrar un sistema inmune in vitro basado en células humanas que imita el microentorno humano in vivo. La plataforma in vitro tiene un gran valor estratégico porque puede predecir el comportamiento y nocividad de medicamentos potenciales en la fase de experimentación preclínica. La empresa busca socios con el fin de establecer acuerdos de investigación y colaboración para validar el sistema, así como asesoramiento y orientación para el desarrollo y aplicación del sistema en un entorno industrial.

Details

Tittle:
Comprehensive in vitro human immune response testing
Summary:
A Dutch-British joint venture is developing a system of biological and analytical assays that combines novel cell lines, 3D scaffolds and primary cells to deliver an in vitro human cell-based immune system that mimics the in vivo human microenvironment. The company aims at a research cooperation agreement and further collaboration to help validate the system. Furthermore, advice and guidance on the development and application of the system in an industrial setting is wanted.
Description:
A Dutch-British company is specialized in biological and analytical preclinical testing of novel drugs and recently developed a novel in vitro testing platform.
The introduction of novel drugs, based on new molecular insight, can be recognized as most promising for our healthcare for the coming decades. They are target specific, can be applied as personalized medicine and can be very effective in contrast to generic medicines. However in order to bring these new compounds to the market as new and registered medicines, extensive clinical trials have to be performed. These trials are very time consuming and costly.
The offered in vitro platform is of strategic great value, since it is able to predict the behaviour and noxiousness of potential drugs in the preclinical testing phase of development. The new testing platform makes the whole route of drug development faster and economically feasible and is therefore highly encouraged by regulatory authorities. The need for improved and more rapid and economical trials is urgent since, due to the success of modern molecular biology, more and better solutions and drug targets will be discovered. It is here that the offered platform may claim great impact.
Crucial to the adoption of the offered platform will be to show proof of principle with relevant drug molecules. The company is seeking (bio)pharmaceutical partners (e.g. drug discovery groups, contract research organisations and biosimilars groups) able to provide compounds to validate their model as well as to help validate the offered in vitro system. Ideally this would include marketed compounds and molecules (with associated data) that failed due to immunogenicity.

The company aims at a research cooperation agreement and is open to discuss also other types of agreements. Furthermore, the company is also seeking advice and guidance on the development and application of the testing platform in an industrial setting.
Advantages and Innovations:
A typical immunogenicity study consists of 60 experimental animals per compound to be studied, including tests such as lymph node assays, histopathology, and determination of antigen-specific and auto- antibodies. The offered technology platform robustly predicts the human immune response, offering a viable alternative approach to replace some of these studies and to ensure only the compounds most likely to be safe and efficacious enter regulatory animal studies.

Advantages in a nutshell:
¿ - Better translation from preclinical studies to humans
¿ - Reduction in the number of animal tests
¿ - A more robust and comprehensive immunologic profile: improved safety and risk prediction thus reducing human health hazard risk
¿ - Drug development can be terminated before costly advanced stages of drug development: reduced investments in non-viable drugs and reduced attrition rate
¿ - Potential to improve drugs and make non-viable drugs accessible to patients
Stage of Development:
Under development/lab tested
IPs:
Secret Know-how,Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
The company has discussed the platform with patent attorneys. They are in the process to apply for patents on the use of the platform as an in vitro human immune system.

Partner sought

Type and Role of Partner Sought:
Industry and academia and actors in the fields of (bio)pharmaceutical development (e.g. drug discovery groups, contract research organisations and biosimilars groups).
A concerted research effort and further business development is needed and is based on the open innovation methodology, bringing together collective intelligence of various industries, companies and knowledge organizations.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
Dutch
English

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001003 Citología, cancerología, oncología
06002007 Ensayos in vitro, experimentos
06001002 Investigaciones clínicas, ensayos
06001015 Productos farmacéuticos / medicamentos